Leerink Partnrs Analysts Lift Earnings Estimates for Pfizer

Pfizer Inc. (NYSE:PFE - Free Report) - Leerink Partnrs lifted their Q2 2025 earnings per share estimates for Pfizer in a report released on Wednesday, April 30th. Leerink Partnrs analyst D. Risinger now expects that the biopharmaceutical company will post earnings of $0.57 per share for the quarter, up from their previous estimate of $0.52. The consensus estimate for Pfizer's current full-year earnings is $2.95 per share. Leerink Partnrs also issued estimates for Pfizer's Q3 2025 earnings at $0.98 EPS, Q4 2025 earnings at $0.67 EPS, FY2025 earnings at $3.14 EPS, FY2028 earnings at $2.65 EPS and FY2029 earnings at $2.22 EPS.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company's quarterly revenue was down 7.8% compared to the same quarter last year. During the same period in the prior year, the business earned $0.82 earnings per share.

A number of other brokerages have also issued reports on PFE. Guggenheim reissued a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. The Goldman Sachs Group reaffirmed a "neutral" rating and set a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Cantor Fitzgerald assumed coverage on Pfizer in a research report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price objective for the company. Citigroup restated a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Finally, UBS Group increased their price target on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $29.17.

Pfizer Stock Up 1.1 %

Shares of PFE opened at $24.19 on Monday. Pfizer has a 52-week low of $20.92 and a 52-week high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock has a fifty day simple moving average of $24.34 and a two-hundred day simple moving average of $25.73. The company has a market capitalization of $137.19 billion, a PE ratio of 17.16, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67.

Hedge Funds Weigh In On Pfizer

A number of large investors have recently modified their holdings of PFE. Retirement Wealth Solutions LLC acquired a new stake in shares of Pfizer in the fourth quarter valued at about $26,000. Rialto Wealth Management LLC purchased a new stake in shares of Pfizer during the fourth quarter valued at approximately $26,000. Clarity Asset Management Inc. purchased a new position in shares of Pfizer in the fourth quarter valued at $27,000. Gould Capital LLC grew its holdings in Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 493 shares in the last quarter. Finally, Kohmann Bosshard Financial Services LLC purchased a new stake in Pfizer during the 4th quarter worth $28,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Pfizer

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of the company's stock in a transaction that occurred on Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the purchase, the director now owns 27,707 shares of the company's stock, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.06% of the stock is currently owned by corporate insiders.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.11%. The ex-dividend date is Friday, May 9th. Pfizer's dividend payout ratio is presently 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.